Penumbra has secured US Food and Drug Administration (FDA) clearance for THUNDERBOLT, expanding the company’s computer-assisted vacuum thrombectomy (CAVT) lineup to address acute ischemic stroke.
The latest product to market for the California-based company, which was acquired by Boston Scientific in a $14.5bn megadeal announced in January 2026, uses CAVT technology to remove clots at the site of occlusion during stroke treatment.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
With FDA clearance in hand, Thunderbolt is poised to join Penumbra’s existing CAVT product lineup, including its Lightning Bolt and Lightning Flash systems for removing blood clots in the arterial, venous and pulmonary vessels. The systems received FDA clearance in 2023 and 2024, respectively.
A joint World Stroke Organization (WSO)–Lancet Neurology Commission from 2023 estimated that the direct and indirect costs of stroke exceeded $891bn on a global basis annually. Meanwhile, unless urgent reformation in stroke care is implemented, such as improvements to evidence-based acute care and rehabilitation services, the same paper projects that the global burden of stroke mortality per annum will increase by 50% to around 9.7 million by 2050, up from 6·6 million in 2020.
Penumbra asserts that Thunderbolt is the first CAVT platform to deliver modulated aspiration for acute ischemic stroke to realise “faster, more complete” clot removal. According to Penumbra president Shruthi Narayan, clearance for the platform represents the beginning of a “new era” in stroke management.
“We are uniquely positioned as the only company offering CAVT technology across both vascular and neurovascular conditions — redefining blood clot care from head-to-toe,” Narayan said.
Boston Scientific’s acquisition of Penumbra was announced during the 2026 J.P. Morgan Healthcare Conference in January. Representing the sole megadeal announced during the event, which typically sees a high level of dealmaking activity, GlobalData’s medical data and analytics director, Alison Casey, pointed out at the time that Boston’s acquisition puts them in direct competition with Stryker in the peripheral thrombectomy market. According to GlobalData’s US SKU tracker, Stryker and Penumbra comprise almost 90% of the total share in the US in this market.
